Curis (CRIS) Q1 2026 earnings review
Accounting Noise Masks a High-Stakes Clinical Execution Story
Curis officially transitioned to a pre-revenue, pure-play biotech in Q1 following the sale of its Erivedge royalties. Headline numbers look terrifying—Net Loss more than doubled YoY to $24.2 million—but this was entirely driven by a $12.7 million non-cash warrant liability charge tied to its January PIPE financing. Operating expenses were relatively stable. The real story is cash runway: current cash of $15.0M is insufficient, meaning survival heavily depends on successfully dosing the fifth patient in the TakeAim CLL study by mid-year. Doing so triggers Series B warrants, unlocking $20.2 million and extending the runway into late 2027.
🐂 Bull Case
If management executes on enrollment and doses the 5th CLL patient by mid-2026, the mandatory Series B warrant exercise injects $20.2M, pushing financial concerns out to the second half of 2027.
Discussions with the FDA and EMA confirmed the ongoing PCNSL Phase 1/2 study can support accelerated approval filings, maintaining a clear regulatory path for the lead asset.
🐻 Bear Case
The company's funding is directly tied to an enrollment milestone (5th CLL patient). If clinical delays occur, Curis will hit a severe liquidity wall with only $15M in current cash.
Following the Q4 2025 sale of Erivedge royalties, Curis reported $0 revenue. The company is now entirely dependent on capital markets and warrant exercises to fund operations.
⚖️ Verdict: ⚪
Neutral. The massive GAAP net loss is an accounting illusion, but the reliance on a single near-term clinical milestone (5th CLL patient dosing) to secure the balance sheet makes this a high-risk, binary setup over the next 3-6 months.
Key Themes
Warrant Liability Crushes GAAP Earnings
Investors should completely ignore the $24.2M net loss. Other expense spiked to $12.7M (up from $0.5M a year ago) due solely to the changing fair value of the warrant liability from the January 2026 PIPE financing. Operating loss actually landed at $11.5M, confirming that core cash burn remains relatively stable.
CLL Trial Dosing Triggers Capital Injection
The TakeAim CLL study is not just a clinical milestone; it is the company's financial lifeline. The January PIPE included Series B warrants that mandate exercise ($20.2M gross proceeds) 30 days after Curis announces it has dosed the fifth patient in the Phase 2 CLL study. Management expects this by mid-2026, making it the single most important catalyst for the stock.
G&A Expenses Decoupling from R&D
While R&D expenses were decelerating (dropping from $8.5M in 25Q1 to $6.4M in 26Q1), General & Administrative expenses jumped to $5.1M (up from $4.0M a year ago). Management attributed this directly to the expenses associated with the January PIPE financing. It highlights the frictional costs of staying afloat in the current biotech market.
Revenue Reversing to Zero
The reality of the Erivedge royalty sale is now visible in the income statement. Revenue has reversed from a steady ~$2.5M per quarter to absolute zero. Without this non-dilutive capital, the company's equity base is entirely responsible for funding the $11M+ quarterly operating burn.
Solid Tumor Data Expansion
While B-cell malignancies are the priority, Curis highlighted ongoing clinical activity in solid tumors. Initial clinical data for emavusertib in combination with FOLFOX and anti-PD1 in gastroesophageal cancers showed a manageable toxicity profile. Additionally, pancreatic ductal adenocarcinoma (PDAC) abstract data is slated for the ASCO meeting in May 2026, providing a potential free option on the pipeline's value.
Other KPIs
Cash increased from $5.1 million at the end of 2025, largely thanks to the initial $20.2M drawn from the January PIPE financing. However, at a normalized operating burn of ~$11M per quarter, this balance sheet provides virtually no margin of safety if the Series B warrants are delayed.
Total liabilities increased from $14.5 million in Q4 2025, driven by a new $1.9 million warrant liability on the balance sheet and a slight uptick in accounts payable/accrued liabilities. This warrant liability will continue to cause non-cash swings in net income in future quarters.
Guidance
Stable. The company expects funding to last into the second half of 2027, but this is highly conditional. It explicitly assumes the receipt of up to $20.2 million from the Series B warrants tied to the CLL trial progress.
Management expects to announce the dosing of the initial 5 patients in the TakeAim CLL combination study with zanubrutinib by mid-2026. This is the critical operational hurdle required to unlock the Series B warrant funding.
The company expects updated clinical data from the PCNSL combination study in the first half of 2027. This timeline highlights that the pivotal data required for the planned accelerated approval filings is still roughly a year away.
Key Questions
CLL Enrollment Visibility
You expect to dose the 5th CLL patient by mid-2026, which triggers vital warrant funding. How many patients have been dosed to date, and what is your contingency plan if enrollment lags behind this critical timeline?
Warrant Liability Volatility
We saw a $12.7 million non-cash charge this quarter due to the warrant liability. How should we model the sensitivity of this liability to your share price going forward, and will Series A or C warrants trigger similar volatility?
PCNSL Enrollment Pace
With data pushed to H1 2027 for the PCNSL study, have you seen any further deceleration in the 'choppy' enrollment rates you described in previous quarters for this ultra-rare indication?